ArticleThoracic cancer2025
The Efficacy of Immune Checkpoint Inhibitors in the EGFR Mutant and Wild-Type Non-Small Cell Lung Cancer Is Positively Associated With the Maturation and Abundance of Dendritic Cells.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDendritic cells (DCs) are known to be crucial in initiating immune responses, but their role in regulating immune checkpoint inhibitor (ICI) efficacy in EGFR mutant NSCLC remains unclear.
methodsPeripheral blood mononuclear cells (PBMCs) were co-cultured with EGFR mutant cells to evaluate immune scores and DC maturation via high-throughput sequencing. TIDE scores were used to predict the efficacy of ICI treatment. Gene set enrichment analysis (GSEA) was carried out on DCs to explore the signaling pathway changes underlying the diverse responses to ICIs.
resultsA significant decrease in CD8+ T lymphocytes and cytotoxicity scores was found in EGFR mutant LUAD compared to wild-type (p < 0.001). Three datasets (GSE135222, GSE126044, and GSE136961) showed that higher DC gene expression was associated with a more favorable response to ICIs (p = 0.028). The CSE241934 dataset showed that the number of conventional DC 1 (cDC1) was higher in the ICI-sensitive group. The TIDE model suggested that cDC1 was associated with ICIs efficacy. However, GSE32863, GSE75037, and GSE72094 showed no differences in cDC subpopulations between EGFR mutant and wild-type LUAD. EGFR mutant cells exhibited more suppression in the expression of HLA-DR, CD40, CD83, and CD86 than the control group. The TIDE model suggested DC maturity was associated with ICI efficacy. GSE241934-IIT showed that DC maturity was more abundant in the ICI-sensitive group than that in the resistant group.
conclusionsBoth the number and maturation capacity of DCs are positively correlated with ICI efficacy. The cause of poor ICI efficacy in EGFR mutant LUAD is more likely to be low DC maturity, not number, compared to EGFR wild-type LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.